WY-50,295 tromethamine: a novel inhibitor of leukotriene-mediated reactions.
Weichman
B M
BM
Immunopharmacology Division, Wyeth-Ayerst Research, Princeton, NJ 08543-8000.
Berkenkopf
J W
JW
Grimes
D
D
Heaslip
R J
RJ
Sturm
R J
RJ
Chang
J Y
JY
D000818:Animals; D000941:Antigens / Q000494:pharmacology; D001249:Asthma / Q000503:physiopathology; D016084:Bronchoconstriction / Q000187:drug effects; D000001:Calcimycin / Q000494:pharmacology; D006168:Guinea Pigs; D006801:Humans; D015289:Leukotrienes / Q000096:biosynthesis*; D016859:Lipoxygenase Inhibitors; D008168:Lung / Q000187:drug effects / Q000378:metabolism; D008264:Macrophages / Q000187:drug effects / Q000378:metabolism; D051379:Mice; D009280:Naphthaleneacetic Acids / Q000494:pharmacology*; D009504:Neutrophils / Q000187:drug effects / Q000378:metabolism; D011804:Quinolines / Q000494:pharmacology*; D051381:Rats; D011971:Receptors, Immunologic / Q000187:drug effects*; D018077:Receptors, Leukotriene; D013189:SRS-A / Q000037:antagonists & inhibitors; D015054:Zymosan / Q000494:pharmacology
D000941:Antigens; D015289:Leukotrienes; D016859:Lipoxygenase Inhibitors; D009280:Naphthaleneacetic Acids; D011804:Quinolines; D011971:Receptors, Immunologic; D018077:Receptors, Leukotriene; D013189:SRS-A; C067525:S(alpha)-methyl-6-(2-quinolinylmethoxy)-2-naphthaleneacetic acid; D000001:Calcimycin; D015054:Zymosan